aTyr Pharma
ATYR
19 hedge funds and large institutions have $6.5M invested in aTyr Pharma in 2019 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 5 increasing their positions, 6 reducing their positions, and 10 closing their positions.
635% more capital inflows, than outflows
Capital inflows: $638K | Capital outflows: $86.8K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
2.71% less ownership
Funds ownership: 50.47% → 47.76% (-2.7%)
17% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 6
21% less funds holding
Funds holding: 24 → 19 (-5)
50% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$228K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$145K |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
+$113K |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$80.6K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$48K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wedbush Securities
Los Angeles,
California
|
-$25K |
| 2 |
Two Sigma Investments
New York
|
-$14K |
| 3 |
Northern Trust
Chicago,
Illinois
|
-$10K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$10K |
| 5 |
Two Sigma Securities
New York
|
-$9K |
ATYR Hedge Fund Activity: Q3 2019 in Review
19 of the 4,576 institutional investors tracked by Wall St. Rank reported a position in aTyr Pharma (ATYR) for Q3 2019, worth a combined $6.5M — down 26% from $8.73M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of ATYR and 5 opened new positions — a net loss of 5 holders — while 6 trimmed existing stakes and 5 added.
The largest buyer was Renaissance Technologies, adding an estimated $228K. The largest seller was Wedbush Securities, exiting entirely with an estimated $25K sold.
- 19 institutional investors held aTyr Pharma (ATYR) as of Q3 2019, down from 24 in Q2 2019.
- Funds reported $6.5M of aTyr Pharma stock for Q3 2019, down 26% quarter-over-quarter.
- 5 funds opened new aTyr Pharma positions in Q3 2019 and 10 closed out, a net change of -5 holders.
- The largest aTyr Pharma buyer in Q3 2019 was Renaissance Technologies, an estimated $228K added.
- The largest aTyr Pharma seller in Q3 2019 was Wedbush Securities, an estimated $25K sold.
Based on aggregated 13F filings for Q3 2019.